The Epidemiology of Autism Spectrum Disorders*

Craig J. Newschaffer,[1] Lisa A. Croen,[2]
Julie Daniels,[3] Ellen Giarelli,[4] Judith K. Grether,[5]
Susan E. Levy,[6] David S. Mandell,[7]
Lisa A. Miller,[8] Jennifer Pinto-Martin,[4]
Judy Reaven,[9] Ann M. Reynolds,[10]
Catherine E. Rice,[11] Diana Schendel,[11]
and Gayle C. Windham[5]

[1]Department of Epidemiology and Biostatistics, Drexel University School of
Public Health, Philadelphia, Pennsylvania 19102; email: cnewscha@drexel.edu

[2]Division of Research, Kaiser Permanente Medical Care Program, Oakland,
California 94612

[3]Department of Epidemiology, University of North Carolina, Chapel Hill,
North Carolina 27599

[4]School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania 19104

[5]Environmental Health Investigations Branch, California Department of
Health Services, Richmond, California 94804

[6]Department of Pediatrics, [7]Department of Psychiatry, University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania 19104

[8]Colorado Department of Public Health and Environment, Denver, Colorado 80246

[9]Department of Pediatrics, [10]University of Colorado, Denver; Health Sciences
Center, JFK Partners, Denver, Colorado 80218

[11]National Center on Birth Defects and Developmental Disabilities, Centers for
Disease Control and Prevention, Atlanta, Georgia 30333

Key Words

prevalence, high-risk groups, risk factors, genetics, environmental
exposures

Abstract

Autism spectrum disorders (ASDs) are complex, lifelong, neurode-
velopmental conditions of largely unknown cause. They are much
more common than previously believed, second in frequency only to
mental retardation among the serious developmental disorders. Al-
though a heritable component has been demonstrated in ASD etiol-
ogy, putative risk genes have yet to be identified. Environmental risk
factors may also play a role, perhaps via complex gene-environment
interactions, but no specific exposures with significant population
effects are known. A number of endogenous biomarkers associated
with autism risk have been investigated, and these may help identify
significant biologic pathways that, in turn, will aid in the discovery of
specific genes and exposures. Future epidemiologic research should
focus on expanding population-based descriptive data on ASDs, ex-
ploring candidate risk factors in large well-designed studies incorpo-
rating both genetic and environmental exposure data and address-
ing possible etiologic heterogeneity in studies that can stratify case
groups and consider alternate endophenotypes.

INTRODUCTION

ASD: autism
spectrum disorder

Autism spectrum disorders (ASDs) are a group
of neurodevelopmental disorders character-
ized by core deficits in three domains: social
interaction, communication, and repetitive or
stereotypic behavior. The degree of impair-
ment among individuals with ASD is vari-
able, but the impact on affected individuals
and their families is universally life-altering.
The condition was initially described in the
U.S. and European medical literature in the
mid-1940s; however, references to individuals
both fictional and historical who apparently
meet the ASD clinical profile go back sev-
eral centuries (178). Through the 1980s ASDs
were believed to be rare, with a prevalence
of no more than 5 per 10,000 persons (53)
and were considered more of an intriguing
clinical dilemma than a major public health
problem. Today, the prevalence of ASDs is
understood to be many times greater, with
the condition now thought to be second only

to mental retardation among the most com-
mon serious developmental disabilities in the
United States (15, 181). With this new un-
derstanding of prevalence, the societal con-
sequences of ASDs, along with the personal
consequences, are beginning to be more fully
appreciated by policymakers.

Frustratingly little is understood about the
causal mechanisms underlying this complex
disorder, and the public health sciences have
only recently begun to study these disorders
in earnest. This review provides an overview
of what is known about the epidemiology of
ASDs including case definition, natural his-
tory, public health impact, descriptive epi-
demiology, genetic epidemiology, and possi-
ble environmental risk factors and biologic
risk markers. Challenges to epidemiologic re-
search are highlighted throughout, and the
chapter concludes by discussing future direc-
tions in ASD epidemiology.

CASE DEFINITION AND NATURAL HISTORY

Diagnosis

ASDs include the three diagnoses: autistic disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS). Here, the term autism refers to this group of diagnoses. No diagnostically informative biologic tests for autism exist. The diagnostic criteria are behavioral, including specific numbers and levels of impairment in the three core domains. Individuals with Asperger's disorder differ from those with autistic disorder because they do not experience significant language delays and consistently have average-to-above-average cognitive skills. Individuals with PDD-NOS show impairment in the core social domain, but their pattern or severity in this or in the other two core domains is insufficient to meet diagnostic criteria for autistic disorder. Recently, standardized interview (99) and direct observation (98) tools have gained acceptance in research settings, and diagnoses based on deficits in reciprocal social interaction and communication have been most reliable (99). However, refinement of tools for diagnosis in routine clinical practice and in research is ongoing. Over the past two decades the field is increasingly understanding that autism encompasses a broader range of impairment than previously thought. The spectrum nature of symptomology does not necessarily imply a single underlying etiology because the range of symptoms could be explained just as easily by multiple etiologies with overlapping impairment profiles.

Natural History

Only in the past several years have researchers been able to diagnose autism reliably as early as two to three years of age (95). Depending on the severity of the disorder, delays have been reported in initial diagnoses of 20–60 months between initial parental suspicion and diagnosis (104, 175). One study of children receiving mental health services through Medicaid in Philadelphia found that, compared with white children, black children received ASD diagnoses almost three years later, on average (103). An autistic disorder diagnosis at age two tends to remain stable, but the early diagnosis of PDD-NOS may change at later ages, most typically to a diagnosis of autistic disorder (97).

ASDs present with a wide range of symptom intensity, and within each diagnostic category multiple domains of function influence the impact of the disorder. The proportion of children with ASDs reported to actually lose acquired language and social skills before the age of two (regression) ranges from 25% to 50% across studies (140). A recent multisite study reported that for most children who experienced regression, development prior to regression was clearly atypical (135). The best known predictors of functional outcome in children with autism are cognitive status, age at language acquisition, and age at diagnosis (105, 169). Prospective studies have generally found that 60%–75% of individuals with autism followed into adulthood experience poor or very poor outcomes (144). However, changes in diagnostic practice and an increase in the availability of early intervention over the past two decades may limit the generalizability of these findings to more recent birth cohorts.

Associated Conditions

Other developmental, behavioral, psychiatric, and medical conditions commonly cooccur with autism. Mental retardation (MR) has historically been an associated diagnosis in 70%–75% of children with autism. However, more recent, epidemiological surveys place the prevalence rates of MR in autism between 40% and 55% (22, 181). Behavioral difficulties may be related to core features (e.g., perseveration, obsessiveness), comorbid diagnoses or symptoms (e.g., aggression, disruption, hyperactivity, self-injury), or sensory abnormalities. Psychiatric symptoms (e.g.,

anxiety, depression) may be influenced by severity of core deficits, cognitive impairments, and/or comorbid medical disorders (54, 82).

In ∼10% of children with autism, specific genetic, neurologic, or metabolic disorders are identified as etiologic factors (47). Many other medical symptoms or disorders are commonly reported in children with autism: seizures (168), immune system dysregulation (173), gastrointestinal symptoms (81), feeding difficulties (e.g., refusal, selectivity, sensitivity to textures), and sleep disruption (130).

Interventions and Treatment Strategies

The first small study documenting positive outcomes in children with ASDs following intensive behavioral intervention was published in the late 1980s (100). Reviews of model programs and accumulated evidence since then have led to recent recommendations that young children with ASDs should receive comprehensive behaviorally based educational intervention (i.e., addressing all the core features of the disorders and associated problems) at a minimum threshold number of hours per week (118). Because the empirical support for these standards is still relatively weak and satisfactory amelioration of symptoms is extremely rare (144), a need persists for more comprehensive studies that can establish guidelines for intervention intensity and duration, age of initiation, and generalizability of strategies across diagnostic and behavioral subgroups of children.

No medications are currently available to treat the core symptoms of ASD. In general, medications are prescribed to address comorbid behaviors such as short attention span, impulsivity/hyperactivity, sleep problems, repetitive/perseverative behaviors, anxious mood, agitation, aggression, and disruptive and self-injurious behaviors (43). Surveys have estimated the prevalence of psychotropic medication use in children as high as 47% (179). Psychopharmacotherapy may enhance behavioral intervention programs by diminishing comorbid behavioral symptoms and improving compliance or response to the treatments, but there is ongoing debate about the role of psychotropic agents (19). Use of complementary and alternative medicine approaches are also commonly reported (90), but their effectiveness remains unproven.

PUBLIC HEALTH IMPACT

Although some evidence suggests that autism may be associated with a reduced lifespan (146), most of the public health burden results from the core impairment and associated morbidities. Preliminary estimates suggest that children with autism have nine times the healthcare expenditures of other Medicaid-eligible children and three times those of children with mental retardation (102). Support services are often required throughout the lifespan, and the associated high costs are evident in the few cost studies available. For example, annual costs associated with care for a child with ASD are estimated to be between 85% and 550% higher than annual cost of care for a typically developing child (71). Average lifetime public expenditures for a person with ASD are estimated to be approximately $4.7 million. Existing national studies of children's health care have not addressed policy and service issues specific to autism (58).

The increased interest in behaviorally based educational intervention has resulted in a push for early identification of autism. However, few pediatricians routinely engage in autism screening (40), and the rates of and average age at identification vary greatly across geographic areas in the United States (104). Although early identification of autism is a public health strategy with great promise, the efficacy and effectiveness of general population-screening instruments have yet to be demonstrated. Moreover, the supply of clinics conducting comprehensive evaluation and treatment planning for children suspected of having ASDs is already outstripped by demand. Although gains have been made in

establishing early intervention programs for young children with autism, regional discrepancies in access still exist, as do large gaps in coordinated intervention strategies for older children and young adults transitioning out of the special education system.

DESCRIPTIVE EPIDEMIOLOGY

Prevalence

The most commonly reported measures of autism frequency are point prevalence or period prevalence. Incidence rates, despite their theoretical advantages for studying risk, are of more limited utility in autism epidemiology because not only is autism diagnosis distal to disease initiation but also time between initiation and diagnosis is likely influenced by a wide range of other factors potentially unrelated to risk. Cumulative incidence, however, may be informative for descriptive epidemiologic studies of birth cohorts (64). Many population-based prevalence surveys of autism have been conducted since the 1960s with a number of recent reviews summarizing these surveys and evaluating changes in reported estimates over time (48, 78, 178). Prevalence time trends for autistic disorder are available for longer time periods than for the ASDs as a group, given that PDD-NOS and Asperger's disorder diagnoses were introduced in 1987 and 1994, respectively. Autistic disorder prevalence estimates centered at ∼5 per 10,000 in the 1960s and 1970s, tended to be ∼10 per 10,000 in the 1980s, and have been highly variable since the 1990s with reported estimates as low as 5 per 10,000 and as high as 72 per 10,000 (76, 152). Several factors associated with the variation in estimates have been noted, including the size and composition of the population studied, the means of conducting initial screening for cases, and the methods and criteria by which cases are confirmed (48, 78, 178). Most recent reviews of the prevalence literature tend to conclude that prevalence of autistic disorder falls between 10 and 20 per 10,000. Recent prevalence estimates for the ASDs collectively have been surprisingly consistent, in comparison with the heterogeneity of autistic disorder estimates, falling close to 60 per 10,000 (7, 13, 22, 23). However, the most recent prevalence survey available at this writing reported ASD prevalence of ASDs in a population of more than 55,000 British eight- and nine-year-olds to be more than 110 per 10,000 (8).

The epidemiologic data coupled with dramatic increases over the past 15 years in the numbers of individuals receiving services from educational and developmental disabilities service agencies under autism classifications (121, 145) have focused attention on the secular trend in autism prevalence and its underlying causes. Some of the trend in administrative data is undoubtedly artifact. For example, the U.S. special education classification of autism was introduced only in 1994, and some of the rise in reported prevalence is certainly related to expansion of the boundaries set for behaviors consistent with an autism phenotype (51, 145, 178). Nonetheless, the question of whether this historical increase can be fully accounted for by these and other changes in diagnosis and classification remains open to debate, largely because it is very difficult to develop quantifiable estimates of diagnostic effects and virtually impossible to prove or disprove temporal changes in autism population risk profiles given the condition's unknown etiology.

High-Risk Groups

Boys are affected with ASDs more frequently than are girls with an average male-to-female ratio of 4.3:1 (48). The sex ratio is modified substantially by cognitive impairment; among cases without mental retardation the sex ratio may be more than 5.5:1, whereas among those with mental retardation the sex ratio may be closer to 2:1 (48). The sex ratio is also influenced by the presence of dysmorphic features with lower male to female ratios and greater frequency of cognitive impairment reported

among cases with the presence of six or more minor dysmorphic features (108).

Little information is available about variations in prevalence by race and ethnicity, and data from U.S. studies are inconsistent. Factors that seem to influence racial and ethnic variability across studies include the case ascertainment approach, consideration of autism subtypes, and immigration status. A California study found prevalence to be higher in children with black mothers, lower in children with Mexican-born mothers, and comparable among children with white, Asian, and U.S.-born Hispanic mothers (29); whereas an Atlanta study found that black-white rates varied by autism subtype on the basis of the cognitive status of the case (181). In national surveys, frequency of parental reports of autism diagnosis is comparable in black and white children but is significantly lower in Hispanic children (142). Studies conducted outside the United States have suggested an increased risk of autism in children who had at least one immigrant parent (53, 101, 177), but this finding was not supported in the California study that found mothers immigrating from Mexico were less likely than U.S.-born Hispanic mothers to have a child with autism (29).

Positive correlations between autism prevalence and various indicators of socioeconomic status have been consistently reported (29, 65, 77, 79). Investigators have long suspected this association to be the result of ascertainment bias (177), with empirical support for this hypothesis emerging recently. However, an Atlanta study found no association between socioeconomic status and autism in children identified only in schools (which provide universal access to services) (79), and a report from Denmark, where access to health care is universal, found no association between autism and parental wealth or education (84).

Reports on the relationship between maternal age and autism prevalence have been inconsistent; some studies show increasing risk with increased maternal age (29, 55, 66)

whereas others find no association (41, 75). A contributing factor to cross-study heterogeneity could be variation by autism subtype: One recent report found the maternal age association to vary by the cognitive impairment status of the case (79). Others have conjectured that maternal age serves as a proxy for another true actual risk factor, paternal age, and have shown positive associations between paternal age and autism prevalence after adjustment for maternal age (20, 87).

GENETIC EPIDEMIOLOGY

Heritability of Autism

The genetic liability to autism was reported first in 1977 on the basis of a study comparing autistic disorder concordance in 11 monozygotic (MZ) and 10 dizygotic (DZ) twin pairs (45). In the early 1990s this study's sample was doubled and standard diagnostic instruments were used, yielding 69% MZ concordance and 0% DZ concordance and providing continuing support for a large heritable component to autism risk (5). Two additional modest-sized twin studies have confirmed large differences in MZ and DZ concordance (137, 153). These existing twin studies exhibited limited statistical precision. Larger, population-based twin studies of autism are underway.

The prevalence of autistic disorder among siblings of individuals with autistic disorder ranges from 2% to 6% (6), with estimates as high as 14% for siblings of females with autistic disorder (138). Even at the lower end of this range, prevalence in siblings is many times higher than is contemporaneous population prevalence estimates, providing additional support for the heritability of autism. Family studies have also shown that ~20% of siblings of probands with autistic disorder may have more subtle variants of the core features of ASDs such as aloofness, lack of tact, limited friendships, poor pragmatic and reciprocal language, and preference for predictable routine, which are collectively referred to as the broad autism phenotype (129). Fewer data

are available on the recurrence rates of specific ASD diagnoses other than autistic disorder and on recurrence of any type of ASD when the index proband has either Asperger's disorder or PDD-NOS.

Taken together, twin studies and family studies clearly establish that a genetic susceptibility to autism exists. Because MZ concordance is less than 100% and the degree of impairment and range of symptoms vary markedly among concordant pairs, environmental factors are most likely etiologically significant as well (5, 89). Should gene environment interaction account for some of the genetic component of autism risk, quantitative estimates of heritability can be substantially overestimated (59).

Although the heritability of autism has been established, the model of inheritance is still not clear. Segregation analyses based on pedigrees of autism families are challenged by the higher likelihood of stoppage (having fewer children than originally planned) in families affected by autism (73). Despite early reports that autism might follow a simple autosomal recessive inheritance model (139), later studies have consistently suggested more complex inheritance. Investigators have found both additive threshold (74) and epistatic models (136) to be the best fit in different sample sets. In general, however, these complex, multigene models seem most consistent with the findings from the broad autism phenotype studies, which suggest that family members with the broad autism phenotype possess fewer predisposing genetic variants than do clinical cases.

Gene-Discovery Studies

Two principal strategies exist for identifying specific autism risk genes. The first is full genome screens that use sets of polymorphic markers distributed over all chromosomes in samples of, often multiplex, autism families. The second is analyses focused on specific candidate genes believed a priori to have functional importance in a biologic mechanism

of potential etiologic relevance to ASDs. To date, results from 10 full genome screens have been published. Findings from all but one (86) have been summarized in recent reviews (4, 80). Genome screen findings have identified numerous regions of suggestive linkage, but only a subset of these overlap across studies. The lack of consistent findings may be attributable to variability in optimal criteria to define "significant" results, the presence of etiologic heterogeneity, and/or complexity of the underlying genetic mechanism.

The regions of interest identified in more than one genome screen are on chromosomes 1p, 2q, 5q, 7q, 15q, 16p, 17q, 19p, and Xq (80). One promising region appears to be the one located on chromosome 7q (4, 80). This region's plausibility is supported by the identification of chromosomal anomalies in this area in individual autism cases, the location of several candidate autism risk genes in the area, and the fact that the region continued to reach significance in a meta-analysis of six independent genome screens (166). However, the findings concerning 7q still vary substantively in terms of localization of the linkage peak and strength of the statistical association, so the region of interest on this chromosome remains quite broad and could contain more than one risk gene.

In the past ten years more than 100 candidate genes have been studied for association with ASDs (4). The fact that the list of specific genes considered is long is no surprise given that more than one third of all human genes are expressed in the developed or developing brain (16) and that there are few specific leads on pathobiologic pathways relevant to ASDs to guide candidate gene selection. Some of the candidate genes that have received the most attention include the serotonin transporter (SLC6A4 or 5-HTT) gene on chromosome 17q, the reelin (RELN) gene and the engrailed gene (EN2) on 7q, and the neuroligin genes (NLGN2 and NLGN4) on Xp and Xq, respectively (12, 131, 148, 182). However, no one has consistently replicated the positive findings for these, or any other,

candidate autism genes. Candidate gene studies must surmount the same major hurdles faced by linkage studies—the potentially complex underlying genetic mechanism and possible etiologic heterogeneity. In addition, the lack of reproducibility of candidate gene studies is potentially a product, in part, of publication bias in initial positive reports and limited statistical power in follow-up investigations.

Genetic epidemiologists have adopted many strategies in an attempt to move the field forward. The first is sample stratification by potential markers of etiologic heterogeneity. This approach involves separating family samples into groups on the basis of case and/or family member phenotypic characteristics and determining whether linkage or association is stronger in one group versus another group. This approach has shown some promise; for example, stratification by presence of language delay increased linkage signals at chromosome 2q (151). Yet, initial reports suggest that heterogeneity of study findings generally seen in candidate gene studies is persisting across the phenotypic subgroups investigated thus far. For example, Bradford et al. (18) reported a strengthening of linkage signal at 7q and 13q in the subsets of families with a history of language delay, but Spence et al. (151) were unable to replicate this finding. Similarly, whereas Molloy et al. (113) found linkage at chromosomes 21q and 7q in a subset with autism and developmental regression, Parr et al. (126) found little evidence for linkage at these sites in their autism family subset with language regression. Other behavioral characteristics that have been used to stratify samples include insistence on sameness, obsessive-compulsive behavior, and the presence of savant skills.

POTENTIAL RISK FACTORS AND RISK MARKERS

Infection and Immune Dysfunction

Converging evidence points toward an immunologic component in an unknown pro-

portion of children with autism. The pathway linking the immune system and autism is still unclear because of limitations in available data and uncertainty about the nature and timing of the neurodevelopmental process that leads to autism. Cerebral spinal fluid and peripheral blood from older children with autism often show atypical levels of autoantibodies to neural antigens, immunoglobulins, inflammatory cytokines, and other markers that may signal dysregulation and/or dysmaturation of both adaptive and innate immune systems (31, 115, 183). Postmortem central nervous sytstem tissue from individuals with autism shows evidence of innate immune system abnormalities, particularly in the cerebellum, which are thought to represent a chronic inflammatory process (171).

Less compelling evidence exists for an initiating role for infection and immune factors during the critical period of early neurodevelopment. Prenatal exposure to viral agents (e.g., cytomegalovirus, rubella) has been linked to autism, but early viral exposure is unlikely to account for many cases (91). Rodent models demonstrate that the maternal immune response to infectious exposure during critical prenatal periods can cause autistic-like behavioral changes in pups, but the applicability to human populations is uncertain (147). Early reports of a high frequency of autoimmune disorders among mothers and other relatives from self-selected subjects were not replicated in a recent population-based study of maternal autoimmune diagnoses recorded in the four-year period surrounding pregnancy (30), although familial autoimmune thyroid disease has been associated with regressive autism in another study (114). A modest association with maternal asthma and allergy diagnoses recorded during the second trimester was observed in one study (30). Limited evidence from candidate gene studies has implicated genes that regulate immune response as autism susceptibility loci (172). Early childhood exposures to antibiotic treatments and measles, mumps, and rubella (MMR) vaccination have been

hypothesized to contribute to risk of autism (42, 69). Empirical support for the antibiotic hypothesis has yet to emerge, and evidence from studies on autism and MMR does not support an association (49, 69).

These findings do not yet permit clarification of whether immune dysfunction during early neurodevelopment leads directly to central nervous system abnormalities, if an inherent central nervous system abnormality triggers an abnormal immune response or if the central nervous system and immune changes occur in parallel.

Neurotransmitters, Peptides, and Growth Factors

Neurotransmitters, neuropeptides, and neurotrophins are families of protein signaling molecules that orchestrate neurodevelopment and neural function through complex, reciprocal communication networks that include the immune and endocrine systems. Certain of these factors have been evaluated as potential contributors to the etiology of autism. As a test of the hypothesis that autism is a result of dysregulation of the normal developmental program in the brain, an initial study sought to evaluate levels of selected neuropeptides and neurotrophins in archived newborn specimens (119). Of eight analytes reported, significant case-control differences were observed for two neuropeptides (CGRP and VIP) and two neurotrophins (BDNF and NT4/5), with similar results for children with autism and children with MR compared with controls. Subsequent immunoassays employing different laboratory platforms have failed, thus far, to replicate these initial findings (120). Some limited evidence in children with autism suggests abnormal levels of BDNF (brain-derived neurotrophic factor) in peripheral blood, but the pathogenic significance of this finding is uncertain (26).

Serotonin, a neurotransmitter, has consistently been found at higher concentrations in peripheral blood of subjects with autism. Selective serotonin reuptake inhibitors (SSRIs)

can ameliorate autistic behaviors in some affected individuals, and some studies indicate that manipulation of serotonin in animal models can lead to pathological findings seen in autistic brains (174). Imaging (25) and genetic studies (37) suggest that autism may be associated with abnormal serotonin synthesis. However, studies of fetal and newborn serotonin synthesis have not been reported, and the etiologic importance of serotonin is unclear. Melatonin is made in the pineal gland from serotonin, with peak secretion at night. Some, but not all, studies have shown decreased nighttime production of melatonin in individuals with autism (164) consistent with the high rate of sleep disorders in individuals with autism (130).

Oxytocin and vasopressin are structurally related peptides that have been linked to processing of social cues, social recognition, and social bonding in mammalian species (68). Polymorphisms in oxytocin receptor genes have been associated with autism in human studies (180), and complex deficits in oxytocin processing appear to be present in some children with autism (112). No association was found in one study between autism and pregnancy induction using exogenous oxytocin (50). Secretin, a peptide active in the gut and brain, was reported anecdotally to show promise as a pharmacologic intervention for autism, but subsequent clinical trials failed to demonstrate significant behavioral improvements in treated children (158).

Endocrine Factors

The study of endocrine factors in autism stems from links with other neuropsychiatric disorders and the persistent gender imbalance yet to be explained by a genetic mechanism. Abnormal sex hormone levels in pregnancy, especially testosterone with its presumed effects on sexually dimorphic brain structure and behavior, is an area of interest. However, exposure assessment is challenging, with amniotic fluid difficult to obtain and the ultimate utility of morphologic markers of in

utero exposure, such as digit length ratios, unproven. The steroid precursors DHEA (dehydroepiandrosterone) and DHEA-S (dehydroepiandrosterone sulfate) have been investigated given their role in regulating neuronal function. One study found lower DHEA and DHEA-S levels in adults with autism than in controls (157), whereas study of pubertal and prepubertal children reported no DHEA-S differences (162).

Maternal reproductive hormone dysregulation may be one mechanism leading to obstetric suboptimalities that have received attention as potential autism risk factors (discussed further in the following section). The rising use of infertility treatments has prompted general interest in their developmental consequences. However, data on infertility history in autism are scant, and elevated rates of autism have not been observed among children born after in vitro fertilization techniques (92, 127, 155). A critical consideration for future investigations is the development of approaches to distinguish the hormonal effects of treatment from other potential treatment effects, such as twinning or premature birth, and from potential effects related to the underlying causes of infertility (including advanced maternal age).

Other hormonal factors of interest have been hypothalamic/pituitary/adrenal (HPA) axis stress hormones and thyroid hormones. Given the high rate of anxiety and heightened arousal symptoms in individuals with autism, stress hormone levels have been investigated in several small case-control studies (32, 161, 163) producing variable results. However, the prenatal maternal stress response, especially before 32 weeks gestation when the fetal limbic system is considered to be most vulnerable (14), may be of potentially greater etiologic significance. Intrauterine thyroid dysfunction has been linked to neurologic deficits and has been hypothesized to contribute to autism and other neurobehavioral disorders (141). One study reported no association between neonatal thyroxine levels and autism (150), but in-

trauterine exposure may be the more relevant measure.

Obstetric Factors

Many studies have investigated associations between autism risk and maternal obstetric characteristics, labor and delivery complications, and neonatal factors. Early studies that generated initial concern tended to be small, lacked adjustment for potential confounding factors, and often relied, in part, on parent's report of obstetric complications (38, 44, 165). Several studies involved the creation of scores summarizing various combinations of maternal and neonatal factors such as maternal age, parity, intrauterine bleeding, infection, caesarian delivery, breech presentation, Rh incompatibility, neonatal birthweight, gestational age, Apgar score, and meconium staining. Most of the studies using composite suboptimality scores reported less optimal pre-, peri-, and neonatal experiences among children with autism compared with both population and sibling controls (52, 96, 154, 159), but the biological mechanism underlying such associations has not been elucidated.

Recently, larger studies have evaluated individual perinatal events. Uterine bleeding, caesarian section, low birthweight, preterm delivery, and low Apgar score are among the few factors that have been more consistently associated with autism (30, 55, 66, 84). Results for most other factors have been more equivocal (30, 66, 84, 154, 159). Methodologic issues continue to challenge the synthesis and interpretation of this body of evidence. The underlying cause of a measured obstetric factor or set of factors is rarely known, nor is the temporal relationship between the obstetric event and the actual biological onset of autism.

Xenobiotic Exposure

There have been relatively few empirical investigations of potentially neurotoxic environmental or other xenobiotic exposures and autism risk, although interest remains high

given the biologic plausibility and the possibility that gene-environment interactions may underlie some of the complexity of autism inheritance (88, 122). The following sections discuss prescription medication and metal exposure, the two areas that have received the most attention to date, as well as other environmental exposures.

Prescription medications. Three medications with known teratogenic properties have been identified as potential autism risk factors. Thalidomide, prescribed in the 1950s and 1960s as a sleeping aid and to treat anxiety and morning sickness, was first linked to autism after a reexamination of 100 Swedish patients exposed to thalidomide during the first trimester of pregnancy. Four subjects met criteria for autistic disorder, suggesting a much higher prevalence of autism in this small thalidomide-exposed population. All four cases were exposed to thalidomide around 20 to 24 days after conception, offering evidence that disruption of neural tube closure may be related to autism early in pregnancy (156). Valproic acid, an antiepileptic drug also used as a mood stabilizer in bipolar disorder and schizophrenia, has been linked with autism on the basis of two small clinical series in which individuals exposed in utero showed high frequencies of autistic features (116, 132). Various animal studies have modeled potential biologic mechanisms behind these associations (67, 111, 143). Finally, survivors of labor-induced abortion using misoprostol have a higher occurrence of certain congenital anomalies, including Mobius syndrome (33). Patients with Mobius syndrome have higher-than-expected rates of autism (72), and in one recent report three out of five children with Mobius syndrome and autism had a history of in utero exposure to misoprostol (10). Although the population attributable risk associated with these relatively rare in utero drug exposures is likely quite small, these reports establish the plausibility of xenobiotic risk factors in autism etiology

and may prove useful as models for pathogenic pathways to autism.

Metals. Several metals have been associated with adverse neurodevelopmental outcomes in children and are also considered potential endocrine disruptors (EDs) (107). Although lead is a known neurotoxin and studies have found adverse effects of prenatal exposure on growth and development, surprisingly little research has been done with respect to autism (107). Mercury also has known adverse neurotoxic effects and has become ubiquitous in the global environment (1). Mercury occurs in several forms: the naturally occurring elemental (as found in outdoor air and dental amalgams), inorganic, and organic, which accumulates in the food chain as methyl mercury (primarily in fish). Several incidents of widespread methyl mercury poisoning resulted in serious neurodevelopmental impairments after prenatal exposure (9, 167), whereas longitudinal studies of less-exposed fish-eating populations have not produced consistent results with respect to cognitive deficits in children (34, 57). Ethyl mercury has been used in medical products, most notably as a preservative (thimerosal) in multi-dose vials of vaccines. Thimerosal contributes to total mercury levels in the blood, but there is little direct evidence of health effects in humans, and expert reviews have found that available evidence does not support a causal association between thimerosal-containing vaccines and autism (69, 125). Studies of mercury concentrations in the hair of autistic children have yielded inconsistent results (63, 70).

Data on the developmental effects of elemental mercury are very limited. In animal studies, prenatal or early postnatal exposure resulted in subtle behavioral changes, hyperactivity, and alterations in spontaneous and learned behaviors (1). An ecologic study of industrial emissions reported a slight association of higher mercury levels with numbers of autistic children in special education, but it did not examine other, or earlier, exposures

(124). A recent study of hazardous air pollutants found a moderate association of autism with estimated airborne metal levels at birth, most notably mercury, cadmium, and nickel (176).

Other environmental exposures. Occupational exposure to solvents at chronic, high levels leads to neurotoxicity. Maternal exposure has been associated with various adverse pregnancy outcomes, including neural tube defects, as well as lower scores among offspring on subtests of intellectual, language, motor, and neurobehavioral functioning (85, 106). The study of hazardous air pollutants noted previously (176) found a moderate association with autism and estimated airborne levels of chlorinated solvents at birth. Higher estimates of diesel particulate matter concentrations during the prenatal period were also moderately associated with autism in that study, but they were also correlated with metal concentrations (176). Animal studies of diesel exhaust suggest permanent alterations in both learning ability and activity and potential endocrine disrupting effects (170). Increased indices of inflammation were seen in brains of mice exposed to airborne particulate matter (21). The relevance of these animal studies to autism is not known, but they suggest potential mechanisms and avenues for further research.

Polychlorinated bi-phenyls (PCBs) are complex mixtures of persistent contaminants stored in lipids, which have demonstrated neurotoxic and endocrine-disrupting effects in animal studies. Longitudinal studies of prenatally exposed children have found an increase in abnormal reflexes, decrease in motor skills, and cognitive deficits (133), but studies to identify autistic behaviors are lacking. Structurally similar to PCBs and found in increasing concentrations in people and the environment, brominated fire retardants (BFRs) such as polybrominated diethyl ether (PBDE) are of concern because they cause a disruption of thyroid hormone function (39). Animal studies of PBDE have indicated effects of developmental exposure on sex steroids, sexually dimorphic behavior, and neurobehavior (93).

Alcohol, Smoking and Illicit Drug Exposure

Alcohol could play a role in autism risk both directly, as a teratogen, and indirectly, via a linked genetic predisposition to both autism and alcoholism. Case reports have been published on a total of nine children affected by both fetal alcohol syndrome (FAS) and autism, or related conditions on either spectrum (2, 60, 117). However, no epidemiologic data on associations between prenatal alcohol exposure and autism risk have emerged yet, and the case report data are insufficient to conclude a link between FAS and autism (46). A number of family history studies reported higher frequency of alcoholism among family members of children with autism than among the family members of controls (109, 128, 149), but other studies found no differences (17, 84).

Smoking, illicit drug use, and other lifestyle exposures often accompany consumption of alcohol. Very few analyses have been performed of smoking in pregnancy and autism, and among completed studies, no consistent pattern has emerged (66, 75, 84). One study of a cohort of infants with prenatal cocaine exposure reported that 11% of children met diagnostic criteria for autism (36). Prenatal cocaine exposure could lead to hyperserotonemia in exposed fetuses (174), a mechanism of potential interest in autism etiology, but interpretation is complicated because of the high maternal coconsumption of other substances, including alcohol and tobacco, that may have exerted independent effects on outcome. For example, tobacco smoke exposure in pregnancy is recognized for its adverse effects on pregnancy outcome and fetal growth and development (28).

FUTURE DIRECTIONS

Although considerable advances in the epidemiologic research on autism have been

made over the past decade, gaps in knowledge remain and methodologic challenges persist. As long as autism remains a behaviorally defined condition, adequately addressing case definition issues will be central to moving forward both descriptive and analytic epidemiology. Interest concerning the meaning of secular trends in autism has been intense, but a lack of confidence in the extent to which past estimates represent true baseline levels of autism as it is now conceptualized fundamentally limit the interpretation of existing secular trend data. To overcome these limitations, prevalence surveys repeated over time in the same population need to use consistent methodology and make extra efforts to hold constant case definition criteria. A record-based autism surveillance system recently implemented in the United States (134), although likely to maintain a consistent methodology over time, still needs to pay special attention to drift in the extent of and manner in which information enters the service delivery evaluation records that provide the source data for this program.

Descriptive epidemiology should also extend beyond counting and characterization of clinically diagnosed cases to find ways to ensure that undiagnosed individuals with significant autism symptoms are also ascertained to assure accurate prevalence estimation and reduce the opportunity for selection bias to influence risk factor studies. The development of valid and reliable approaches for identifying affected persons in diverse cultures with differing public health infrastructures, however, is a challenge. Investigators need to collect additional data on the distribution of sociodemographic characteristics and traditional pre- and perinatal risk factors in samples representative of different populations. Epidemiologic inquiry in diverse populations may reveal informative variations in risk reflective of important genetic, phenotypic, or exposure variation, and assuming differences in ascertainment and diagnosis can be ruled out, may thereby provide clues to underlying etiology.

Expanded efforts are also needed to identify autism risk factors. There is certainly room for more adequately sized, well-designed studies of risk biomarkers and xenobiotic exposures. There are a number of environmental exposures, including potential endocrine disruptors such as phthalates and phenols used in plastic products, pesticides, and PBDEs, that have known neurodevelopmental effects, as well as heavy metals that may be important to consider in further risk factor investigations. Risk factor studies may be aided by case-group stratification, begun recently in candidate-gene studies because this may help overcome barriers to risk factor discovery posed by etiologic heterogeneity. Of course, behavioral domains, the most popular stratification factors so far, have not been established as important in constructing etiologically homogenous subgroups. Physical features such as head circumference, presence of gastrointestinal symptoms, or circulating serotonin levels may prove more effective for this purpose. Complex combinations of behavioral, genetic, and other biomedical characteristics may ultimately provide the most effective subtyping of autism cases.

A closely related strategy is focused analysis of phenotypic features common in autism as possible intermediate outcomes: endophenotypes. Endophenotypes are defined as heritable characteristics that might have simpler, but related, genetic roots to ASDs (56). Individual behavioral traits often considered in stratification may also be reasonable candidates for autism endophenotypes. For example, a recently developed continuous measure of social relatedness, the social reciprocity scale, may have potential as a tool characterizing an autism endophenotype (27).

Another innovative area in autism epidemiology is that of epigenetics, the study of heritable genetic factors that are not part of the DNA sequence. These likely add to the underlying complexity of disease susceptibility. One type of epigenetic factor of interest in autism is genomic imprinting, where a specific parental allele is preferentially expressed

in somatic cells of the offspring because of DNA methylation or histone modifications. Many imprinted genes are highly expressed in the brain (35), and some other known genetic disorders associated with autistic features and diagnoses, such as Prader-Willi and Angelman syndromes, result from defects in imprinting or the aberrant expression of imprinted genes (123). At this point only a few autism linkage studies have incorporated examination of parent-of-origin effects, which could elucidate epigenetic mechanisms (3, 83, 94). Epidemiologic studies looking to explore gene expression, however, face the additional challenge of inaccessibility of tissue from the organ of primary interest: the brain.

Future breakthroughs could also come from other areas. Gene-environment interaction is receiving increased attention (61, 88, 122), and large studies with the capacity to explore gene-environment hypotheses are now in the field (62). These studies have also begun to supplement binary diagnostic endpoints with data on continuous endophenotypes. Given the very early onset of abnormal development, evidence from neuroanatomic studies (11), and etiologic links to some known teratogens, there is a high likelihood that autism pathology originates in utero. Consequently, prenatal environmental exposures and gene-environment interactions involving maternal genes, such as those contributing to regulation of the intrauterine environment or detoxification of exogenous exposures during gestation, could be of prime etiologic significance. The exploration of these direct maternal genetic effects has

already begun in some candidate gene studies on the basis of case-parent trio data (24), although optimal designs to test these hypotheses involve the collection of additional genotypic data on grandparents (110). Furthermore, studies of endogenous biomarkers such as the neurotrophic, immune, and endocrine factors, in utero, at birth, and very early in life could also offer clues about dysregulated processes that might, in turn, lead to investigations of candidate genes or specific exposures known to influence these pathways. Pilot studies designed to measure exposures and biomarkers in pregnant women who already have one child with autism and prospectively follow the at-risk newborn are already under development (160). However, biomarker investigations in these studies, as with gene-expression analyses, must make use of samples collected from accessible tissue compartments.

Epidemiologic knowledge of autism should expand markedly over the next decade as more representative descriptive data accumulate and comprehensive and innovative risk factor investigations begin to yield results. Our evolved understanding of autism—once thought to be a rare condition of psychogenic origin—as a disorder with a range of phenotypes, complex genetic susceptibility, and multiple potential etiologies has influenced the design of current epidemiologic research. Although this reality is more challenging, it provides the proper context for epidemiology and other sciences to work toward much needed advances.

SUMMARY POINTS

1. Autism spectrum disorders (ASDs) are neurodevelopmental conditions with complex phenotypes and, most likely, several underlying etiologies.

2. The prevalence of ASDs in developed countries is now considered to be at least 60 per 10,000.

3. ASDs occur more commonly in boys, although the gender ratio depends on cognitive status and presence of minor dysmorphology.

4. More children are being diagnosed with ASDs today than in the past. Some of the prevalence increase is undoubtedly attributable to changing diagnostic tendency; however, there are insufficient data to determine whether this can explain the entire increasing trend.

5. ASDs are heritable, but the model of inheritance is very complex, probably involving multiple susceptibility genes. One of these yet-to-be-identified genes can probably be found on chromosome 7q. Other susceptibility genes may interact with environmental exposures or be subject to epigenetic influence.

6. A link between environmental exposures and ASDs is plausible, but little evidence exists supporting associations between specific environmental exposures and autism. Furthermore, it is not yet clear whether any specific exposures will have substantive population impact. Knowledge gained from studies of signaling proteins and endocrine factors may inform future risk factor investigations.

ACKNOWLEDGMENT

LITERATURE CITED

1. Agency Toxic Subst. Dis. Reg. (ATSDR). 1999. *Toxicological profile for mercury*. Atlanta, GA. **http://www.atsdr.cdc.gov/toxprofiles/tp46.html**

2. Aronson M, Hagberg B, Gillberg C. 1997. Attention deficits and autistic spectrum problems in children exposed to alcohol during gestation: a follow-up study. *Dev. Med. Child Neurol.* 39:583–87

3. Ashley-Koch A, Wolpert CM, Menold MM, Zaeem L, Basu S, et al. 1999. Genetic studies of autistic disorder and chromosome 7. *Genomics* 61:227–36

4. Bacchelli E, Maestrini E. 2006. Autism spectrum disorders: molecular genetic advances. *Am. J. Med. Genet. C. Semin. Med. Genet.* 142:13–23

5. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, et al. 1995. Autism as a strongly genetic disorder: evidence from a British twin study. *Psychol. Med.* 25:63–77

6. Bailey A, Palferman S, Heavey L, Le Couteur A. 1998. Autism: the phenotype in relatives. *J. Autism Dev. Disord.* 28:369–92

7. Baird G, Charman T, Baron-Cohen S, Cox A, Swettenham J, et al. 2000. A screening instrument for autism at 18 months of age: a 6-year follow up study. *J. Am. Acad. Child Adolesc. Psychiatry* 39:694–702

8. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, et al. 2006. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the special needs and autism project (SNAP). *Lancet* 368:210–15

9. Bakir F, Damluji SF, Amin-Zaki L, Murtadha M, Khalidi A, et al. 1973. Methylmercury poisoning in Iraq. *Science* 181:230–41

10. Bandim JM, Ventura LO, Miller MT, Almeida HC, Costa AE. 2003. Autism and mobius sequence: an exploratory study of children in northeastern Brazil. *Arq. Neuropsiquiatr.* 61:181–85

11. Bauman ML, Kemper TL. 2005. Neuroanatomic observations of the brain in autism: a review and future directions. *Int. J. Dev. Neurosci.* 23:183–87

12. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, et al. 2005. Support for the homeobox transcription factor gene ENGRAILED 2 as an autism spectrum disorder susceptibility locus. *Am. J. Hum. Genet*. 77:851–68

13. Bertrand J, Mars A, Boyle C, Bove C, Yeargin-Allsopp M, Decoufle P. 2001. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. *Pediatrics* 108:1155–61

14. Beversdorf DQ, Manning SE, Hillier A, Anderson SL, Nordgren RE, et al. 2005. Timing of prenatal stressors and autism. *J. Autism Dev. Disord*. 35:471–78

15. Bhasin TK, Brocksen S, Avchen RN, Van Naarden Braun K. 2006. Prevalence of four developmental disabilities among children aged 8 years—metropolitan Atlanta developmental disabilities surveillance program, 1996 and 2000. *MMWR Surveill. Summ*. 55:1–9

16. Boguski MS, Jones AR. 2004. Neurogenomics: at the intersection of neurobiology and genome sciences. *Nat. Neurosci*. 7:429–33

17. Bolton PF, Pickles A, Murphy M, Rutter M. 1998. Autism, affective and other psychiatric disorders: patterns of familial aggregation. *Psychol. Med*. 28:385–95

18. Bradford Y, Haines J, Hutcheson H, Gardiner M, Braun T, et al. 2001. Incorporating language phenotypes strengthens evidence of linkage to autism. *Am. J. Med. Genet*. 105:539–47

19. Bryson SE, Rogers SJ, Fombonne E. 2003. Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management. *Can. J. Psychiatry* 48:506–16

20. Burd L, Severud R, Kerbeshian J, Klug MG. 1999. Prenatal and perinatal risk factors for autism. *J. Perinat. Med*. 27:441–50

21. Campbell A, Oldham M, Becaria A, Bondy SC, Meacher D, et al. 2005. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. *Neurotoxicology* 26:133–40

22. Chakrabarti S, Fombonne E. 2001. Pervasive developmental disorders in preschool children. *JAMA* 285:3093–99

23. Chakrabarti S, Fombonne E. 2005. Pervasive developmental disorders in preschool children: confirmation of high prevalence. *Am. J. Psychiatry* 162:1133–41

24. Cheslack-Postava K, Fallin M, Avramopoulos D, Connors S, Zimmerman A, et al. 2005. *Polymorphisms in the gene for á2 adrenergic receptor and risk for autism in the AGRE cohort*. Presented at Int. Meet. Autism Res. (IMFAR), May 5–7, Boston

25. Chugani CD, Muzik O, Behen M, Rothermel R, Janisse JJ, et al. 1999. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. *Ann. Neurol*. 45:287–95

26. Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, et al. 2006. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. *Biol. Psychiatry* 59:354–63

27. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, et al. 2003. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. *J. Autism Dev. Disord*. 33:427–33

28. Cornelius MD, Day NL. 2000. The effects of tobacco use during and after pregnancy on exposed children. *Alcohol. Res. Health*. 24:242–49

29. Croen LA, Grether JK, Selvin S. 2002. Descriptive epidemiology of autism in a California population: Who is at risk? *J. Autism Dev. Disord*. 32:217–24

30. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. 2005. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. *Arch. Pediatr. Adolesc. Med*. 159:151–57

31. Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, et al. 2002. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. *Psychol. Med.* 32:1457–63

32. Curin JM, Terzic J, Petkovic ZB, Zekan L, Terzic IM, Susnjara IM. 2003. Lower cortisol and higher ACTH levels in individuals with autism. *J. Autism Dev. Disord.* 33:443–48

33. da Silva Dal Pizzol T, Knop FP, Mengue SS. 2007. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. *Reprod. Toxicol.* In press

34. Davidson PW, Myers GJ, Cox C, Axtell C, Shamlaye C, et al. 1998. Effects of prenatal and postnatal methylmercury exposure from fish consumption on neurodevelopment: outcomes at 66 months of age in the Seychelles Child Development Study. *JAMA* 280:701–7

35. Davies W, Isles AR, Wilkinson LS. 2005. Imprinted gene expression in the brain. *Neurosci. Biobehav. Rev.* 29:421–30

36. Davis E, Fennoy I, Laraque D, Kanem N, Brown G, Mitchell J. 1992. Autism and developmental abnormalities in children with perinatal cocaine exposure. *J. Natl. Med. Assoc.* 84:315–19

37. Devlin B, Cook EHJ, Coon H, Dawson G, Grigorenko EL, et al. 2005. Autism and the serotonin transporter: the long and short of it. *Mol. Psychiatry* 10:1110–16

38. Deykin EY, MacMahon B. 1980. Pregnancy, delivery, and neonatal complications among autistic children. *Am. J. Dis. Child.* 134:860–64

39. Donald TA. 2002. A perspective on the potential health risks of PBDEs. *Chemosphere* 46:745–55

40. Dosreis S, Weiner CL, Johnson L, Newschaffer CJ. 2006. Autism spectrum disorder screening and management practices among general pediatric providers. *J. Dev. Behav. Pediatr.* 27:S88–94

41. Eaton WW, Mortensen PB, Thomsen PH, Frydenberg M. 2001. Obstetric complications and risk for severe psychopathology in childhood. *J. Autism Dev. Disord.* 31:279–85

42. Fallon J. 2005. Could one of the most widely prescribed antibiotics amoxicillin/clavulanate "augmentin" be a risk factor for autism? *Med. Hypotheses* 64:312–15

43. Findling RL. 2005. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. *J. Clin. Psychiatry* 66(Suppl. 10):26–31

44. Finegan J, Quarrington B. 1979. Pre, peri, and neonatal factors and infantile autism. *J. Child Psychol. Psychiatry* 20:119–28

45. Folstein S, Rutter M. 1977. Genetic influences and infantile autism. *Nature* 265:726–28

46. Fombonne E. 2002. Is exposure to alcohol during pregnancy a risk factor for autism? *J. Autism Dev. Disord.* 32:243

47. Fombonne E. 2003. Epidemiological surveys of autism and other pervasive developmental disorders: an update. *J. Autism Dev. Disord.* 33:365–82

48. Fombonne E. 2005. Epidemiological studies of pervasive developmental disorders. In *Handbook of Autism and Pervasive Developmental Disorders*, ed. F Volkmar, R Paul, A Klin, D Cohen, pp. 42–69. Hoboken, NJ: Wiley

49. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. 2006. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. *Pediatrics* 118:e139–50

50. Gale S, Ozonoff S, Lainhart J. 2003. Brief report: pitocin induction in autistic and nonautistic individuals. *J. Autism Dev. Disord.* 33:205–8

51. Gernsbacher MA, Dissanayake C, Goldsmith HH, Mundy PC, Rogers SJ, Sigman M. 2005. Autism and deficits in attachment behavior. *Science* 307:1201–3

52. Gillberg C, Gillberg IC. 1983. Infantile autism: a total population study of reduced optimality in the pre, peri-, and neonatal period. *J. Autism Dev. Disord*. 13:153–66

53. Gillberg C, Steffenburg S, Schaumann H. 1991. Is autism more common now than ten years ago? *Br. J. Psychiatry* 158:403–9

54. Gillott A, Furniss F, Walter A. 2001. Anxiety in high-functioning children with autism. *Autism* 5:277–86

55. Glasson EJ, Bower C, Petterson B, de Klerk N, Chaney G, Hallmayer JF. 2004. Perinatal factors and the development of autism: a population study. *Arch. Gen. Psychiatry* 61:618–27

56. Gottesman II, Gould TD. 2003. The endophenotype concept in psychiatry: etymology and strategic intentions. *Am. J. Psychiatry* 160:636–45

57. Grandjean P, Weihe P, White RF, Debes F, Araki S, et al. 1997. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. *Neurotoxicol. Teratol*. 19:417–28

58. Guevara JP, Mandell DS, Rostain AL, Zhao H, Hadley TR. 2003. National estimates of health services expenditures for children with behavioral disorders: an analysis of the medical expenditure panel survey. *Pediatrics* 112:e440

59. Guo SW. 2000. Gene-environment interaction and the mapping of complex traits: some statistical models and their implications. *Hum. Hered*. 50:286–303

60. Harris SR, MacKay LLJ, Osborn JA. 2002. Autistic behaviors in offspring of mothers abusing alcohol and other drugs: a series of case reports. *Alcohol. Clin. Exp. Res*. 19:660–65

61. Herbert MR, Russo JP, Yang S, Roohi J, Blaxill M, et al. 2006. Autism and environmental genomics. *Neurotoxicology*. 27:671–84

62. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. 2006. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. *Environ. Health Perspect*. 114:1119–25

63. Holmes AS, Blaxill MF, Haley BE. 2003. Reduced levels of mercury in first baby haircuts of autistic children. *Int. J. Toxicol*. 22:277–85

64. Honda H, Shimizu Y, Imai M, Nitto Y. 2005. Cumulative incidence of childhood autism: a total population study of better accuracy and precision. *Dev. Med. Child Neurol*. 47:10–18

65. Hoshino Y, Kumashiro H, Yashima Y, Tachibana R, Watanabe M. 1982. The epidemiological study of autism in Fukushima-ken. *Folia Psychiatr. Neurol. Jpn*. 36:115–24

66. Hultman CM, Sparen P, Cnattingius S. 2002. Perinatal risk factors for infantile autism. *Epidemiology* 13:417–23

67. Ingram JL, Peckham SM, Tisdale B, Rodier PM. 2000. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. *Neurotoxicol. Teratol*. 22:319–24

68. Insel TR, Young LJ. 2000. Neuropeptides and the evolution of social behavior. *Curr. Opin. Neurobiol*. 10:784–89

69. Inst. Med. 2004. *Immunization Safety Review: Vaccines and Autism*. Washington, DC: Natl. Acad. Press

70. Ip P, Wong V, Ho M, Lee J, Wong W. 2004. Mercury exposure in children with autistic spectrum disorder: case-control study. *J. Child Neurol*. 19:431–34

71. Jacobson JW, Mulick JA. 2000. System and cost research issues in treatments for people with autistic disorders. *J. Autism Dev. Disord*. 30:585–93

72. Johansson M, Wentz E, Fernell E, Stromland K, Miller MT, Gillberg C. 2001. Autistic spectrum disorders in Mobius sequence: a comprehensive study of 25 individuals. *Dev. Med. Child Neurol*. 43:338–45

73. Jones MB, Szatmari P. 1988. Stoppage rules and genetic studies of autism. *J. Autism Dev. Disord*. 18:31–40

74. Jorde LB, Hasstedt SJ, Ritvo ER, Mason-Brothers A, Freeman BJ, et al. 1991. Complex segregation analysis of autism. *Am. J. Hum. Genet*. 49:932–38

75. Juul-Dam N, Townsend J, Courchesne E. 2001. Prenatal, perinatal, and neonatal factors in autism, pervasive developmental disorder-not otherwise specified, and the general population. *Pediatrics* 107:E63

76. Kadesjo B, Gillberg C, Hagberg B. 1999. Brief report: Autism and Asperger syndrome in seven-year-old children: a total population study. *J. Autism Dev. Disord*. 29:327–31

77. Kanner L. 1943. Autistic disturbances of affective contact. *Nerv. Child*. 2:217–50

78. Karapurkar T, Lee NL, Curran LK, Newschaffer CJ, Yeargin-Allsopp M. 2003. Autistic spectrum disorders in children. In *Autistic Spectrum Disorders in Children*, pp. 17–42. Madison, NY: Marcel Dekker

79. Karapurkar-Bhasin T, Schendel D. 2007. Sociodemographic risk factors for autism in a U.S. metropolitan area. *J. Aut. Dev. Dis*. In press

80. Klauck SM. 2006. Genetics of autism spectrum disorder. *Eur. J. Hum. Genet*. 14:714–20

81. Kuddo T, Nelson KB. 2003. How common are gastrointestinal disorders in children with autism? *Curr. Opin. Pediatr*. 15:339–43

82. Lainhart JE, Folstein SE. 1994. Affective disorders in people with autism: a review of published cases. *J. Autism Dev. Disord*. 24:587–601

83. Lamb JA, Barnby G, Bonora E, Sykes N, Bacchelli E, et al. 2005. Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. *J. Med. Genet*. 42:132–37

84. Larsson HJ, Eaton WW, Madsen KM, Vestergaard M, Olesen AV, et al. 2005. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. *Am. J. Epidemiol*. 161:916–25

85. Laslo-Baker D, Barrera M, Knittel-Keren D, Kozer E, Wolpin J, et al. 2004. Child neurodevelopmental outcome and maternal occupational exposure to solvents. *Arch. Pediatr. Adolesc. Med*. 158:956–61

86. Lauritsen MB, Als TD, Dahl HA, Flint TJ, Wang AG, et al. 2006. A genome-wide search for alleles and haplotypes associated with autism and related pervasive developmental disorders on the Faroe islands. *Mol. Psychiatry* 11:37–46

87. Lauritsen MB, Pedersen CB, Mortensen PB. 2005. Effects of familial risk factors and place of birth on the risk of autism: a nationwide register-based study. *J. Child Psychol. Psychiatry* 46:963–71

88. Lawler CP, Croen LA, Grether JK, Van de Water J. 2004. Identifying environmental contributions to autism: provocative clues and false leads. *Ment. Retard. Dev. Disabil. Res. Rev*. 10:292–302

89. Le Couteur A, Bailey A, Goode S, Pickles A, Robertson S, et al. 1996. A broader phenotype of autism: the clinical spectrum in twins. *J. Child Psychol. Psychiatry* 37:785–801

90. Levy SE. 2003. *Complementary and alternative medical treatments for children with autism spectrum disorders: emotion or evidence-based?* Presented at Nemours Adv. Autism Res. Symp., May 19, Nemours Child. Clin., duPont Hosp. Child., Wilmington, Deleware

91. Libbey JE, Sweeten TL, McMahon WM, Fujinami RS. 2005. Autistic disorder and viral infections. *J. Neurovirol*. 11:1–10

92. Lidegaard O, Pinborg A, Andersen AN. 2005. Imprinting diseases and IVF: Danish national IVF cohort study. *Hum. Reprod*. 20:950–54

93. Lilienthal H, Hack A, Roth-Harer A, Grande SW, Talsness CE. 2006. Effects of developmental exposure to 2,2,4,4,5-pentabromodiphenyl ether (PBDE-99) on sex steroids, sexual development, and sexually dimorphic behavior in rats. *Environ. Health Perspect*. 114:194–201

94. Liu J, Nyholt DR, Magnussen P, Parano E, Pavone P, et al. 2001. A genomewide screen for autism susceptibility loci. *Am. J. Hum. Genet.* 69:327–40

95. Lord C. 1995. Follow-up of two-year-olds referred for possible autism. *J. Child Psychol. Psychiatry* 36:1365–82

96. Lord C, Mulloy C, Wendelboe M, Schopler E. 1991. Pre- and perinatal factors in high-functioning females and males with autism. *J. Autism Dev. Disord.* 21:197–209

97. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A. 2006. Autism from 2 to 9 years of age. *Arch. Gen. Psychiatry* 63:694–701

98. Lord C, Risi S, Lambrecht L, Cook EHJ, Leventhal BL, et al. 2000. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J. Autism Dev. Disord.* 30:205–23

99. Lord C, Rutter M, Le Couteur A. 1994. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J. Autism Dev. Disord.* 24:659–85

100. Lovaas OI. 1987. Behavioral treatment and normal educational and intellectual functioning in young autistic children. *J. Consult. Clin. Psychol.* 55:3–9

101. Magnusson P, Saemundsen E. 2001. Prevalence of autism in Iceland. *J. Autism Dev. Disord.* 31:153–63

102. Mandell DS, Cao J, Ittenbach R, Pinto-Martin J. 2006. Medicaid expenditures for children with autistic spectrum disorders: 1994 to 1999. *J. Autism Dev. Disord.* 36:475–85

103. Mandell DS, Listerud J, Levy SE, Pinto-Martin JA. 2002. Race differences in the age at diagnosis among Medicaid-eligible children with autism. *J. Am. Acad. Child Adolesc. Psychiatry* 41:1447–53

104. Mandell DS, Novak MM, Zubritsky CD. 2005. Factors associated with age of diagnosis among children with autism spectrum disorders. *Pediatrics* 116:1480–86

105. McGovern CW, Sigman M. 2005. Continuity and change from early childhood to adolescence in autism. *J. Child Psychol. Psychiatry* 46:401–8

106. McMartin KI, Chu M, Kopecky E, Einarson TR, Koren G. 1998. Pregnancy outcome following maternal organic solvent exposure: a meta-analysis of epidemiologic studies. *Am. J. Ind. Med.* 34:288–92

107. Mendola P, Selevan SG, Gutter S, Rice D. 2002. Environmental factors associated with a spectrum of neurodevelopmental deficits. *Ment. Retard. Dev. Disabil. Res. Rev.* 8:188–97

108. Miles JH, Takahashi TN, Bagby S, Sahota PK, Vaslow DF, et al. 2005. Essential versus complex autism: definition of fundamental prognostic subtypes. *Am. J. Med. Genet. A.* 135:171–80

109. Miles JH, Takahashi TN, Haber A, Hadden L. 2003. Autism families with a high incidence of alcoholism. *J. Autism Dev. Disord.* 33:403–15

110. Mitchell LE, Weinberg CR. 2005. Evaluation of offspring and maternal genetic effects on disease risk using a family-based approach: the "pent" design. *Am. J. Epidemiol.* 162:676–85

111. Miyazaki K, Narita N, Narita M. 2005. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. *Int. J. Dev. Neurosci.* 23:287–97

112. Modahl C, Green L, Fein D, Morris M, Waterhouse L, et al. 1998. Plasma oxytocin levels in autistic children. *Biol. Psychiatry* 43:270–77

113. Molloy CA, Keddache M, Martin LJ. 2005. Evidence for linkage on 21q and 7q in a subset of autism characterized by developmental regression. *Mol. Psychiatry* 10:741–46

114. Molloy CA, Morrow AL, Meinzen-Derr J, Dawson G, Bernier R, et al. 2006. Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: a CPEA study. *J. Autism Dev. Disord.* 36:317–24

115. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, et al. 2006. Elevated cytokine levels in children with autism spectrum disorder. *J. Neuroimmunol.* 172:198–205

116. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, et al. 2000. A clinical study of 57 children with fetal anticonvulsant syndromes. *J. Med. Genet.* 37:489–97

117. Nanson JL. 1992. Autism in fetal alcohol syndrome: a report of six cases. *Alcohol. Clin. Exp. Res.* 16:558–65

118. Natl. Res. Counc. 2001. *Educating Children with Autism.* Washington, DC: Natl. Acad. Press

119. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, et al. 2001. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. *Ann. Neurol.* 49:597–606

120. Nelson PG, Kuddo T, Song EY, Dambrosia JM, Kohler S, et al. 2006. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. *Int. J. Dev. Neurosci.* 24:73–80

121. Newschaffer CJ, Falb MD, Gurney JG. 2005. National autism prevalence trends from United States special education data. *Pediatrics* 115:e277–82

122. Newschaffer CJ, Fallin D, Lee NL. 2003. Heritable and nonheritable risk factors for autism spectrum disorders. *Epidemiol. Rev.* 24:137–53

123. Nicholls RD, Knepper JL. 2001. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. *Annu. Rev. Genomics Hum. Genet.* 2:153–75

124. Palmer RF, Blanchard S, Stein Z, Mandell D, Miller C. 2006. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. *Health Place* 12:203–9

125. Parker SK, Schwartz B, Todd J, Pickering LK. 2004. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. *Pediatrics* 114:793–804

126. Parr JR, Lamb JA, Bailey AJ, Monaco AP. 2006. Response to paper by Molloy et al.: linkage on 21q and 7q in autism subset with regression. *Mol. Psychiatry* 11:617–19

127. Pinborg A, Loft A, Schmidt L, Andersen AN. 2003. Morbidity in a Danish national cohort of 472 IVF/ICSI twins, 1132 non-IVF/ICSI twins and 634 IVF/ICSI singletons: health-related and social implications for the children and their families. *Hum. Reprod.* 18:1234–43

128. Piven J, Palmer P. 1999. Psychiatric disorder and the broad autism phenotype: evidence from a family study of multiple-incidence autism families. *Am. J. Psychiatry* 156:557–63

129. Piven J, Palmer P, Jacobi D, Childress D, Arndt S. 1997. Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. *Am. J. Psychiatry* 154:185–90

130. Polimeni MA, Richdale AL, Francis AJ. 2005. A survey of sleep problems in autism, Asperger's disorder and typically developing children. *J. Intellect. Disabil. Res.* 49:260–68

131. Ramoz N, Reichert JG, Corwin TE, Smith CJ, Silverman JM, et al. 2006. Lack of evidence for association of the serotonin transporter gene SLC6A4 with autism. *Biol. Psychiatry.* 60:186–91

132. Rasalam AD, Hailey H, Williams JH, Moore SJ, Turnpenny PD, et al. 2005. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. *Dev. Med. Child Neurol.* 47:551–55

133. Ribas-Fito N, Sala M, Kogevinas M, Sunyer J. 2001. Polychlorinated biphenyls (PCBs) and neurological development in children: a systematic review. *J. Epidemiol. Community Health* 55:537–46

134. Rice CE, Baio J, Van Naarden Braun K, Doernberg N, Meaney FJ, et al. 2007. A public health collaboration for the surveillance of the autism spectrum disorders (ASDs). *Paed. Peri. Epi.* In press

135. Richler J, Luyster R, Risi S, Hsu WL, Dawson G, et al. 2006. Is there a "regressive phenotype" of autism spectrum disorder associated with the measles-mumps-rubella vaccine? A CPEA study. *J. Autism Dev. Disord.* 36:299–316

136. Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, et al. 1999. A genomic screen of autism: evidence for a multilocus etiology. *Am. J. Hum. Genet.* 65:493–507

137. Ritvo ER, Freeman BJ, Mason-Brothers A, Mo A, Ritvo AM. 1985. Concordance for the syndrome of autism in 40 pairs of afflicted twins. *Am. J. Psychiatry* 142:74–77

138. Ritvo ER, Jorde LB, Mason-Brothers A, Freeman BJ, Pingree C, et al. 1989. The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. *Am. J. Psychiatry* 146:1032–36

139. Ritvo ER, Spence MA, Freeman BJ, Mason-Brothers A, Mo A, Marazita ML. 1985. Evidence for autosomal recessive inheritance in 46 families with multiple incidences of autism. *Am. J. Psychiatry* 142:187–92

140. Rogers SJ. 2004. Developmental regression in autism spectrum disorders. *Ment. Retard. Dev. Disabil. Res. Rev.* 10:139–43

141. Sadamatsu M, Kanai H, Xu X, Liu Y, Kato N. 2006. Review of animal models for autism: implication of thyroid hormone. *Congenit Anom (Kyoto)* 46:1–9

142. Schieve LA, Rice C, Boyle C. 2006. Mental health in the United States: parental report of diagnosed autism in children age 4–17 years–United States 2003–2004. *MMWR* 55:481–86

143. Schneider T, Przewlocki R. 2005. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. *Neuropsychopharmacology* 30:80–89

144. Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS. 2004. Trajectory of development in adolescents and adults with autism. *Ment. Retard. Dev. Disabil. Res. Rev.* 10:234–47

145. Shattuck PT. 2006. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. *Pediatrics* 117:1028–37

146. Shavelle RM, Strauss D. 1998. Comparative mortality of persons with autism in California, 1980–1996. *J. Insur. Med.* 30:220–25

147. Shi L, Tu N, Patterson PH. 2005. Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. *Int. J. Dev. Neurosci.* 23:299–305

148. Skaar DA, Shao Y, Haines JL, Stenger JE, Jaworski J, et al. 2005. Analysis of the RELN gene as a genetic risk factor for autism. *Mol. Psychiatry* 10:563–71

149. Smalley SL, McCracken J, Tanguay P. 1995. Autism, affective disorders, and social phobia. *Am. J. Med. Genet.* 60:19–26

150. Soldin OP, Lai S, Lamm SH, Mosee S. 2003. Lack of a relation between human neonatal thyroxine and pediatric neurobehavioral disorders. *Thyroid* 13:193–98

151. Spence SJ, Cantor RM, Chung L, Kim S, Geschwind DH, Alarcon M. 2006. Stratification based on language-related endophenotypes in autism: attempt to replicate reported linkage. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* 141:591–98

152. Sponheim E, Skjeldal O. 1998. Autism and related disorders: epidemiological findings in a Norwegian study using ICD-10 diagnostic criteria. *J. Autism Dev. Disord.* 28:217–27

153. Steffenburg S, Gillberg C, Hellgren L, Andersson L, Gillberg IC, et al. 1989. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. *J. Child Psychol. Psychiatry* 30:405–16

154. Stein D, Weizman A, Ring A, Barak Y. 2006. Obstetric complications in individuals diagnosed with autism and in healthy controls. *Compr. Psychiatry* 47:69–75

155. Stromberg B, Dahlquist G, Ericson A, Finnstrom O, Koster M, Stjernqvist K. 2002. Neurological sequelae in children born after in-vitro fertilisation: a population-based study. *Lancet* 359:461–65

156. Stromland K, Nordin V, Miller M, Akerstrom B, Gillberg C. 1994. Autism in thalidomide embryopathy: a population study. *Dev. Med. Child Neurol.* 36:351–56

157. Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, et al. 2005. Lowered DHEA-S plasma levels in adult individuals with autistic disorder. *Eur. Neuropsychopharmacol.* 15:305–9

158. Sturmey P. 2005. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. *Res. Dev. Disabil.* 26:87–97

159. Sugie Y, Sugie H, Fukuda T, Ito M. 2005. Neonatal factors in infants with autistic disorder and typically developing infants. *Autism* 9:487–94

160. Szipr M. 2006. Tracing the origins of autism: a spectrum of new studies. *EHP* 114:A412–18

161. Tani P, Lindberg N, Matto V, Appelberg B, Nieminen-von Wendt T, et al. 2005. Higher plasma ACTH levels in adults with Asperger syndrome. *J. Psychosom. Res.* 58:533–36

162. Tordjman S, Anderson GM, McBride PA, Hertzig ME, Snow ME, et al. 1995. Plasma androgens in autism. *J. Autism Dev. Disord.* 25:295–304

163. Tordjman S, Anderson GM, McBride PA, Hertzig ME, Snow ME, et al. 1997. Plasma beta-endorphin, adrenocorticotropin hormone, and cortisol in autism. *J. Child Psychol. Psychiatry* 38:705–15

164. Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. 2005. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. *Biol. Psychiatry* 57:134–38

165. Torrey EF, Hersh SP, McCabe KD. 1975. Early childhood psychosis and bleeding during pregnancy. *J. Autism Child. Schizophr.* 5:287–97

166. Trikalinos TA, Karvouni A, Zintzaras E, Ylisaukko-oja T, Peltonen L, et al. 2006. A heterogeneity-based genome search meta-analysis for autism-spectrum disorders. *Mol. Psychiatry* 11:29–36

167. Tsubaki T, Irukayama K, eds. 1977. *Minamata Disease: Methylmercury Poisoning in Minamata and Niigata, Japan*, New York: Elsevier

168. Tuchman R, Rapin I. 2002. Epilepsy in autism. *Lancet Neurol.* 1:352–58

169. Turner LM, Stone WL, Pozdol SL, Coonrod EE. 2006. Follow-up of children with autism spectrum disorders from age 2 to age 9. *Autism* 10:243–65

170. U.S. Environ. Prot. Agency (USEPA). 2002. Health assessment document for diesel engine exhaust. *Rep. EPA/600/8-90/057F*, Off. Res. Dev., Natl. Cent. Environ. Assess., Washington, DC

171. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. 2005. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann. Neurol.* 57:67–81

172. Warren RP, O'Dell JD, Warren WL, Burger RA, Maciulis A, et al. 1996. Strong association of the third hypervariable region of HLA-DRá1 with autism. *J. Neuroimmunol.* 67:97–102

173. Warren RP, Singh VK, Averett RE, Odell JD, Maciulis A, et al. 1996. Immunogenetic studies in autism and related disorders. *Mol. Chem. Neuropathol.* 28:77–81

174. Whitaker-Azmitia PM. 2005. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? *Int. J. Dev. Neurosci.* 23:75–83

175. Wiggins LD, Baio J, Rice C. 2006. Examination of the time between first evaluation and first autism spectrum diagnosis in a population-based sample. *J. Dev. Behav. Pediatr.* 27:S79–87

176. Windham GC, Zhang L, Gunier R, Croen LA, Grether JK. 2006. Autism spectrum disorders in relation to distribution of hazardous air pollutants in the San Francisco bay area. *Environ. Health Perspect.* 114:1438–44

177. Wing L. 1980. Childhood autism and social class: a question of selection? *Br. J. Psychiatry* 137:410–17

178. Wing L, Potter D. 2002. The epidemiology of autistic spectrum disorders: Is the prevalence rising? *Ment. Retard. Dev. Disabil. Res. Rev.* 8:151–61

179. Witwer A, Lecavalier L. 2005. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. *J. Child Adolesc. Psychopharmacol.* 15:671–81

180. Wu S, Jia M, Ruan Y, Liu J, Guo Y, et al. 2005. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. *Biol. Psychiatry* 58:74–77

181. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. 2003. Prevalence of autism in a US metropolitan area. *JAMA* 289:49–55

182. Ylisaukko-oja T, Rehnstrom K, Auranen M, Vanhala R, Alen R, et al. 2005. Analysis of four neuroligin genes as candidates for autism. *Eur. J. Hum. Genet.* 13:1285–92

183. Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, et al. 2005. Cerebrospinal fluid and serum markers of inflammation in autism. *Pediatr. Neurol.* 33:195–201

DISCLOSURE STATEMENT

Contents

Social Environment and Behavior

Environmental and Occupational Health

Health Services

Public Health Practice

Indexes

Errata

An online log of corrections to *Annual Review of Public Health* chapters (if any, 1997
to the present) may be found at http://publhealth.annualreviews.org/